Table 3.
Kaplan-Meier (KM) Overall Survival, Progression-Free Survival, and Triple-Endpoint Survival Probabilities at 12, 24, 36, 48, and 60 Months
| NHL | MM | |||
|---|---|---|---|---|
| Placebo | Plerixafor | Placebo | Plerixafor | |
| Overall Survival (OS) | ||||
| KM 12 month OS Probability, % (95% CI) | 85 (76, 91) | 87 (81, 91) | 96 (91, 98) | 95 (90, 98) |
| KM 24 month OS Probability, % (95% CI) | 71 (59, 80) | 78 (71, 83) | 87 (79, 92) | 87 (79, 92) |
| KM 36 month OS Probability, % (95% CI) | 61 (49, 72) | 72 (65, 78) | 77 (67, 84) | 77 (69, 84) |
| KM 48 month OS Probability, % (95% CI) | 60 (48, 70) | 68 (60, 74) | 67 (57, 76) | 70 (60, 77) |
| KM 60 month OS Probability, % (95% CI) | 56 (44, 67) | 64 (56, 71) | 64 (53, 73) | 64 (54, 72) |
| Progression-Free Survival (PFS) | ||||
| KM 12 month PFS Probability, % (95% CI) | 72 (62, 81) | 75 (68, 80) | 88 (81, 92) | 83 (76, 88) |
| KM 24 month PFS Probability, % (95% CI) | 66 (55, 76) | 66 (58, 72) | 63 (53, 72) | 57 (48, 65) |
| KM 36 month PFS Probability, % (95% CI) | 54 (42, 65) | 58 (50, 65) | 46 (35, 55) | 38 (30, 47) |
| KM 48 month PFS Probability, % (95% CI) | 48 (36, 59) | 54 (46, 61) | 34 (25, 44) | 24 (17, 32) |
| KM 60 month PFS Probability, % (95% CI) | 43 (31, 54) | 50 (42, 58) | 30 (21,40) | 17 (10, 24) |
| Triple-Endpoint Survival (TES) | ||||
| KM 12 month TES Probability, % (95% CI) | 60 (49, 69) | 60 (52, 66) | 64 (56, 72) | 64 (56, 71) |
| KM 24 month TES Probability, % (95% CI) | 55 (44, 65) | 49 (42, 56) | 43 (34, 53) | 42 (33, 50) |
| KM 36 month TES Probability, % (95% CI) | 44 (33, 55) | 41 (34, 49) | 28 (19, 38) | 27 (20, 35) |
| KM 48 month TES Probability, % (95% CI) | 38 (27, 49) | 40 (32, 47) | 19 (11, 28) | 16 (10, 24) |
| KM 60 month TES Probability, % (95% CI) | 31 (20, 42) | 37 (29, 44) | 14 (7, 23) | 11 (6, 17) |